Simultaneous inhibition of ATR and PARP greatly sensitizes colon cancer cell lines to irinotecan

被引：0
|
作者：
Davidson, David [1 ]
Abu-Sanad, Atlal [1 ]
Wang, Yunzhe [1 ]
Hasheminasab, Fatemeh [1 ]
Panasci, Justin [1 ]
Aloyz, Raquel [1 ]
Panasci, Lawrence [1 ]
机构：
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Insitute, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-5327
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5327
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan
    Abu-Sanad, Atlal
    Wang, Yunzhe
    Hasheminasab, Fatemeh
    Panasci, Justin
    Noe, Alycia
    Rosca, Lorena
    Davidson, David
    Amrein, Lilian
    Sharif-Askari, Bahram
    Aloyz, Raquel
    Panasci, Lawrence
    FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [2] ATR and PARP inhibition enhances topoisomerase I-dependent DNA damage in colon cancer cell lines
    Abu-Sanad, Atlal
    Davidson, David
    Wang, Yunzhe
    Pollard, John
    Aloyz, Raquel
    Panasci, Lawrence
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05)
  • [3] PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation
    IJff, Marloes
    van Bochove, Gregor G. W.
    Whitton, Denise
    Winiarczyk, Roy
    Honhoff, Celina
    Rodermond, Hans
    Crezee, Johannes
    Stalpers, Lukas J. A.
    Franken, Nicolaas A. P.
    Oei, Arlene L.
    CANCERS, 2021, 13 (09)
  • [4] The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
    David Davidson
    Yunzhe Wang
    Raquel Aloyz
    Lawrence Panasci
    Investigational New Drugs, 2013, 31 : 461 - 468
  • [5] The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
    Davidson, David
    Wang, Yunzhe
    Aloyz, Raquel
    Panasci, Lawrence
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 461 - 468
  • [6] Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
    Williams, Sybil M. Genther
    Kuznicki, Apryle M.
    Andrade, Paula
    Dolinski, Brian M.
    Elbi, Cem
    O'Hagan, Ronan C.
    Toniatti, Carlo
    CANCER CELL INTERNATIONAL, 2015, 15
  • [7] Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
    Sybil M Genther Williams
    Apryle M Kuznicki
    Paula Andrade
    Brian M Dolinski
    Cem Elbi
    Ronan C O’Hagan
    Carlo Toniatti
    Cancer Cell International, 15
  • [8] Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
    Charles-André Philip
    Ido Laskov
    Marie-Claude Beauchamp
    Maud Marques
    Oreekha Amin
    Joanna Bitharas
    Roy Kessous
    Liron Kogan
    Tahira Baloch
    Walter H. Gotlieb
    Amber Yasmeen
    BMC Cancer, 17
  • [9] Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
    Philip, Charles-Andre
    Laskov, Ido
    Beauchamp, Marie-Claude
    Marques, Maud
    Amin, Oreekha
    Bitharas, Joanna
    Kessous, Roy
    Kogan, Liron
    Baloch, Tahira
    Gotlieb, Walter H.
    Yasmeen, Amber
    BMC CANCER, 2017, 17
  • [10] Parp inhibition sensitizes brca deficient cancer cell lines and tumors to clinical x-ray and proton irradiation
    Ben Kacem, Mariam
    Bright, Scott J.
    Turner, Broderick X.
    Flint, David B.
    Manandhar, Mandira
    Martinus, David
    Sawakuchi, Gabriel O.
    Shaitelman, Simona F.
    CANCER RESEARCH, 2022, 82 (04)
12345